Bedwetting May Improve After Adenotonsillectomy for Sleep Apnea
Findings seen in secondary analysis of data for children randomly assigned to adenotonsillectomy or watchful waiting for nonsevere OSA
Sleep Apnea
Recall of Philips Breathing Machines Affects Millions of Americans
About 2 million of the recalled machines were in use in the United States
Obstructive Sleep Apnea May Raise Risk for Sudden Death
Meta-analysis shows sleep apnea linked to increased risk for sudden death, cardiovascular mortality
MPR Weekly Dose Podcast Episode 68
This week we cover a caution about remdesivir; New and updated Emergency Use Authorizations; And new approvals in sleep apnea and for Botox.
Novel Rx Device for Sleep Apnea, Snoring Gets FDA Approval
The eXciteOSA device is used while the individual is awake and provides electrical muscle stimulation through a mouthpiece that sits around the tongue.
Inspire Therapy Approved for Younger Patients With Obstructive Sleep Apnea
The Food and Drug Administration (FDA) has expanded the approval of Inspire therapy (Inspire Medical Systems) to include patients aged 18 to 21 years with moderate to severe obstructive sleep apnea (OSA) who are unable to use continuous positive airway pressure (CPAP). Previously, the therapy was only approved for patients 22 years of age and…
Sleep Apnea Traits May Predict Response to Oral Appliance Tx
Response more likely with favorable nonpharyngeal traits, moderate pharyngeal collapsibility
Sunosi Approved for Excessive Daytime Sleepiness With Narcolepsy, OSA
Jazz Pharmaceuticals announced that the Food and Drug Administration (FDA) has approved Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
Patients With Diabetes at Increased Risk for Sleep Apnea
In addition to known predictors of apnea, diabetes-related foot disease, insulin treatment up risk
Patients With Sleep Apnea Have Increased Gout Risk
Among OSA patients, risk for developing gout is highest one to two years after the index date
